Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Status:
Completed

Trial end date:
2019-10-18

Target enrollment:

Participant gender:

The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901)

Phase 1

Radius Health, Inc.
Radius Pharmaceuticals, Inc.

Estrogens